Company: PRTA
Filing Date: 2025-11-06
Form Type: DEFA14A
Source: 0001193125-25-269620
Chunk: 5

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: DEFA14A
Chunk 5
---
 quarter and first nine months of 2025 was primarily from collaboration revenue from Bristol
Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation. Total revenue for the first nine months of 2024, was primarily from collaboration revenue from Bristol Myers Squibb.

Research and development (R&D) expenses totaled $28.9 million and $120.3 million for the third quarter and first nine months of 2025,
respectively, as compared to $50.7 million and $172.3 million for the third quarter and first nine months of 2024, respectively. The decrease in R&D expenses for the third quarter and first nine months of 2025 compared to the same
periods in the prior year was primarily due to lower clinical trial expenses, lower personnel expenses, lower manufacturing and lower consulting expenses. R&D expenses included non-cash share-based
compensation expense of $2.5 million and $12.0 million for the third quarter and first nine months of 2025, respectively, as compared to $5.1 million and $16.2 million for the third quarter and first nine months of 2024,
respectively.

General and administrative (G&A) expenses totaled $13.2 million and $46.7 million for the third quarter and first nine months
of 2025, respectively, as compared to $16.8 million and $50.4 million for the third quarter and first nine months of 2024, respectively. The decrease in G&A expenses for the third quarter and first nine months of 2025 compared to the
same periods in the prior year was primarily due to lower personnel expenses. G&A expenses included non-cash share-based compensation expense of $4.7 million and $16.5 million for the third
quarter and first nine months of 2025, respectively, as compared to $5.9 million and $19.2 million for the third quarter and first nine months of 2024, respectively.

Total non-cash share-based compensation expense was $7.2 million for the third quarter of 2025 and
$30.6 million for the first nine months of 2025 which included $2.1 million in non-cash share-based compensation expense related to restructuring charges, as compared to $11.0 million and
$35.4 million for the third quarter and first nine months of 2024, respectively.

As of September 30, 202